Evidence Table 14Efficacy of new 5HT1D-receptor agonists

ReportNo. of patients with positive responseOdds ratio (95% confidence interval)
active treatmentcontrol/comparison
HEADACHE RELIEF AT 2 HRS
Rizatriptan (MK-462)
40 mg vs. placebo
Cutler, Claghorn, Sramek, et al., 1996
#54220
27/36 (75%)7/21 (33%)6 (1.8 to 20)
Zolmitriptan (311C90)
1 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
6/22 (27%)3/20 (15%)2.1 (0.45 to 9.9)
5 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
13/21 (62%)3/20 (15%)9.2 (2.0 to 41)
25 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
17/21 (81%)3/20 (15%)24 (4.7 to 123)
COMPLETE RELIEF AT 2 HRS
Zolmitriptan (311C90)
1 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
2/22 (9%)1/20 (5%)1.9 (0.16 to 21)
5 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
3/21 (14%)1/20 (5%)3.1 (0.31 to 31)
25 mg vs. placebo
Visser, Klein, Cox, et al., 1996
#55380
8/21 (38%)1/20 (5%)11 (1.3 to 96)

From: Evidence Tables

Cover of Self-Administered Drug Treatments for Acute Migraine Headache
Self-Administered Drug Treatments for Acute Migraine Headache.
Technical Reviews, No. 2.4.
Gray RN, McCrory DC, Eberlein K, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.